SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
Report of Foreign Private Issuer
Pursuant to Rule13a-16 or15d-16
of the Securities Exchange Act of 1934
May 15, 2018
| | |
GlaxoSmithKline plc GlaxoSmithKline Capital plc | | GlaxoSmithKline Capital Inc. |
| (Name of registrant) | | (Name of registrant) |
| | |
980 Great West Road, Brentford, Middlesex, TW8 9GS | | 1105 North Market Street, Suite 1300,
Wilmington, Delaware 19801 |
| (Address of principal executive offices) | | (Address of principal executive offices) |
Indicate by check mark whether the registrant files or will file annual reports under cover Form20-F or Form40-F.
Form20-F ☒ Form40-F ☐
Indicate by check mark if the registrant is submitting theForm 6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting theForm 6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
THIS REPORT ON FORM6-K SHALL BE DEEMED TO BE INCORPORATED BY REFERENCE IN THE PROSPECTUS INCLUDED IN THE REGISTRATION STATEMENT ON FORMF-3 (FILE NOS.333-223982,333-223982-01 AND333-223982-02) OF GLAXOSMITHKLINE PLC, GLAXOSMITHKLINE CAPITAL PLC AND GLAXOSMITHKLINE CAPITAL INC. AND TO BE A PART THEREOF FROM THE DATE ON WHICH THIS REPORT IS FURNISHED, TO THE EXTENT NOT SUPERSEDED BY DOCUMENTS OR REPORTS SUBSEQUENTLY FILED OR FURNISHED.
GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GlaxoSmithKline Capital Inc. hereby incorporate by reference the following exhibits to this report on Form6-K into their Registration Statement on FormF-3 (File Nos.333-223982,333-223982-01,333-223982-02).
| | |
Exhibit No. | | Description of Document |
| |
4.1 | | Second Supplemental Indenture, dated as of May 15, 2018, among GlaxoSmithKline Capital plc, GlaxoSmithKline plc and Deutsche Bank Trust Company Americas. |
| |
4.2 | | Third Supplemental Indenture, dated as of May 15, 2018, among GlaxoSmithKline Capital Inc., GlaxoSmithKline plc and Deutsche Bank Trust Company Americas. |
| |
5.1 | | Opinion of Cleary Gottlieb Steen & Hamilton LLP, special U.S. counsel to GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GlaxoSmithKline Capital Inc. |
| |
5.2 | | Opinion of Cleary Gottlieb Steen & Hamilton LLP, special English counsel to GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GlaxoSmithKline Capital Inc. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned, thereunto duly authorised.
| | | | | | |
| | |
| | | | GlaxoSmithKline plc |
| | |
| | | | GlaxoSmithKline Capital plc and |
| | |
| | | | GlaxoSmithKline Capital Inc. |
| | |
| | | | (Registrants) |
| | | |
| Date: May 15, 2018 | | | | | | |
| | | |
| | | | By: | | /s/ Victoria Whyte |
| | | | Victoria Whyte |
| | | | Authorised Signatory for and on behalf of |
| | | | GlaxoSmithKline plc |
| | | | GlaxoSmithKline Capital plc and |
| | | | GlaxoSmithKline Capital Inc. |
